ArticleJournal of cardiac failure2014
A combined-biomarker approach to clinical phenotyping renal dysfunction in heart failure.
Article in Journal of cardiac failure, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury.Circulation · 2018Trial
- Urine peptidome analysis in cardiorenal syndrome reflects molecular processes.Scientific reports · 2021Article
- Article
- Impacts of right ventricular function and venous congestion on renal response during depletion in acute heart failure.ESC heart failure · 2020Article
- The role of the kidney in acute and chronic heart failure.Heart failure reviews · 2020Review
- Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function.Circulation. Heart failure · 2019Article
- Ultrasonic evaluation of renal cortex arterial area enables differentiation between hypertensive and glomerulonephritis-related chronic kidney disease.International urology and nephrology · 2017Article
- Acute Kidney Injury in Heart Failure Revisited-The Ameliorating Impact of "Decongestive Diuresis" on Renal Dysfunction in Type 1 Acute Cardiorenal Syndrome: Accelerated Rising Pro B Naturetic Peptide Is a Predictor of Good Renal Prognosis.Journal of clinical medicine · 2017Review
- Acute coronary syndrome and acute kidney injury: role of inflammation in worsening renal function.BMC cardiovascular disorders · 2017Article
- Worsening Renal Function and Mortality in Heart Failure: Causality or Confounding?Circulation. Heart failure · 2017Article
- The risk of death associated with proteinuria in heart failure is restricted to patients with an elevated blood urea nitrogen to creatinine ratio.International journal of cardiology · 2016Article
- Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney.Critical care (London, England) · 2015Article
- Perioperative heart-type fatty acid binding protein is associated with acute kidney injury after cardiac surgery.Kidney international · 2015Article
- Kidney disease in heart failure: the importance of novel biomarkers for type 1 cardio-renal syndrome detection.Internal and emergency medicine · 2015Review
- The kidney in heart failure: an update.European heart journal · 2015 · on this mapReview
- Chronic Heart Failure and Comorbid Renal Dysfunction - A Focus on Type 2 Cardiorenal Syndrome.Current cardiology reviewsReview
- Patient Selection and End Point Definitions for Decongestion Studies in Acute Decompensated Heart Failure: Part 1.Journal of the Society for Cardiovascular Angiography & InterventionsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundDifferentiating heart failure (HF) induced renal dysfunction (RD) from intrinsic kidney disease is challenging. It has been demonstrated that biomarkers such as B-type natriuretic peptide (BNP) or the blood urea nitrogen to creatinine ratio (BUN/creat) can identify high- vs low-risk RD. Our objective was to determine if combining these biomarkers could further improve risk stratification and clinical phenotyping of patients with RD and HF. METHODS AND
resultsA total of 908 patients with a discharge diagnosis of HF were included. Median values were used to define elevated BNP (>1296 pg/mL) and BUN/creat (>17). In the group without RD, survival was similar regardless of BNP and BUN/creat (n = 430, adjusted P = .52). Similarly, in patients with both a low BNP and BUN/creat, RD was not associated with mortality (n = 250, adjusted hazard ratio [HR] = 1.0, 95% confidence interval [CI] 0.6-1.6, P = .99). However, in patients with both an elevated BNP and BUN/creat those with RD had a cardiorenal profile characterized by venous congestion, diuretic resistance, hypotension, hyponatremia, longer length of stay, greater inotrope use, and substantially worse survival compared with patients without RD (n = 249, adjusted HR = 1.8, 95% CI 1.2-2.7, P = .008, P interaction = .005).
conclusionsIn the setting of decompensated HF, the combined use of BNP and BUN/creat stratifies patients with RD into groups with significantly different clinical phenotypes and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.